Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Hematologic Malignancy

Interventions: Drug: Entospletinib
Drug: Daunorubicin
Drug: Cytarabine

First Posted Date: 2017-05-01

Last Posted Date: 2020-03-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 9

Registration Number: NCT03135028

Locations: 🇯🇵
University of Fukui Hospital, Fukui, Japan
🇯🇵
Tokai University Hospital, Kanagawa, Japan
🇯🇵
Tohoku University Hospital, Miyagi, Japan

and more 3 locations

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
Acute Lymphoblastic Lymphoma

First Posted Date: 2017-04-18

Last Posted Date: 2024-11-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 790

Registration Number: NCT03117751

Locations: 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸
St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺
The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

and more 5 locations

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: AML

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: Lenalidomide
Drug: Mitoxantrone

First Posted Date: 2017-04-18

Last Posted Date: 2024-04-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 41

Registration Number: NCT03118466

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myelodysplastic Syndrome/Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Cytarabine
Other: Laboratory Biomarker Analysis
Drug: Decitabine
Biological: Nivolumab
Drug: Midostaurin

First Posted Date: 2017-03-28

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT03092674

Locations: 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 503 locations

Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors

Phase 2

Completed

Conditions: Leptomeningeal Metastasis

Interventions: Drug: MTX
Drug: Ara-C
Radiation: Radiotherapy

First Posted Date: 2017-03-17

Last Posted Date: 2019-08-01

Lead Sponsor: The First Hospital of Jilin University

Target Recruit Count: 53

Registration Number: NCT03082144

Locations: 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China

Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Blinatumomab
Procedure: Autologous stem cell transplant
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Procedure: Peripheral blood draws

First Posted Date: 2017-03-07

Last Posted Date: 2023-11-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 14

Registration Number: NCT03072771

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Selinexor
Drug: Fludarabine
Drug: Cytarabine
Drug: methotrexate/hydrocortisone/cytarabine

First Posted Date: 2017-03-06

Last Posted Date: 2020-05-22

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 37

Registration Number: NCT03071276

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States

and more 4 locations

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Phase 3

Active, not recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Placebo
Drug: Venetoclax
Drug: Cytarabine

First Posted Date: 2017-03-03

Last Posted Date: 2024-06-27

Lead Sponsor: AbbVie

Target Recruit Count: 211

Registration Number: NCT03069352

Locations: 🇺🇸
H. Lee Moffit Cancer Center /ID# 164273, Tampa, Florida, United States
🇺🇸
Norton Cancer Institute /ID# 158998, Louisville, Kentucky, United States
🇦🇷
Cemic /Id# 159676, Buenos Aires, Argentina

and more 106 locations

Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

Phase 1

Conditions: AML

Interventions: Drug: Cytarabine
Drug: all-trans retinoic acid
Drug: Arsenic Trioxide

First Posted Date: 2017-01-25

Last Posted Date: 2020-03-20

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 80

Registration Number: NCT03031249

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Efficacy and Safety of Chidamide in CBF Leukemia

Phase 1

Conditions: AML

Interventions: Drug: Cytarabine
Drug: Chidamide

First Posted Date: 2017-01-25

Last Posted Date: 2019-03-22

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 250

Registration Number: NCT03031262

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy